Monitoring of Perfusion in Sepsis and Malaria

Malaria Clinical Trial

— PERFuSE  

Official title:

Perfusion and Lung Congestion Evaluation Related to Fluids and Vasopressors in Sepsis and Malaria. (PERFuSE): an Observational Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03641534
• Other study ID #: MAL18001
• Status: Completed
• Start date: June 4, 2018
• Est. completion date: September 26, 2019

Study information

• Verified date: September 2020
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Sepsis and severe malaria together contribute to an estimated 13 million deaths annually, a great burden of which is in low-income countries. Optimal fluid management is critical yet remains one of the most challenging clinical care elements as volume overload precipitates pulmonary edema and volume restriction may exacerbate acute kidney injury. These complications of sepsis and severe malaria significantly increase mortality, particularly in resource-limited settings lacking mechanical ventilation and renal replacement therapy. Point-of-care ultrasound and passive leg raise testing are two easily implementable, safe and non-invasive clinical bedside fluid assessment tools that could be applied towards developing a fluid management algorithm in low resource settings. Similarly, simple tissue perfusion measures can facilitate understanding of precise indications or contraindication to fluid and vasopressor therapy.

However, the performance of these tools has yet to be confirmed in these settings. Accurate assessment of pulmonary tolerance and fluid responsive patients could aid to tailor vasopressor and fluid therapy to the patient condition and disease phase, thus preventing or detecting iatrogenic pulmonary edema and other pulmonary complications. As there is currently limited evidence supporting fluid management recommendations for severe malaria and sepsis in low-resource settings, the potential application of these management tools could optimize supportive therapy and improve outcomes in these populations.

The main activity proposed is a prospective, observational study of patients with sepsis and severe malaria to describe the relationship between fluid therapy and vasopressor therapy against measures of tissue perfusion and pulmonary congestion in adult patients with severe malaria or severe sepsis. In addition, the study will assess the performance of simple bedside clinical tools assessing fluid responsiveness, pulmonary congestion and peripheral tissue perfusion.

The data from this observational study will facilitate the preparation of a follow-up study to test a clinical algorithm to guide individualized fluid and vasopressor administration.

Description:

This will be a single center, prospective, longitudinal, observational study of patients with sepsis or severe malaria. It is planned that this initial observational study will inform a follow-up intervention study, based on the observational study findings (Lung Ultrasound and Passive Leg Raising- guided Vasopressors and Fluid Management in Patients with Sepsis and Severe Malaria). The follow-up study will propose testing of a clinical algorithm to individualize titration of vasopressors, diuretics and fluids based on the simple tools evaluated during the observational study.

The expected duration of study patient participation is 30 days. Patients will be assessed every 6 hours until fever clearance, parasite clearance (in malaria patients) and GCS normalization (score of 15) on two consecutive assessments. Thereafter, patients will be assessed daily until discharge or death with one follow-up visit at 14 days and a follow-up call at day 30. The prospective, observational recruitment phase of the study is expected to last 15 months.

Funder: Wellcome Trust of Great Britain, Grant reference number: 220211/A/20/Z

Recruitment information / eligibility

• Status: Completed
• Enrollment: 103
• Est. completion date: September 26, 2019
• Est. primary completion date: August 29, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

I. Sepsis criteria:

The sepsis criteria include the severe sepsis and septic shock categories according to 2012 Surviving Sepsis Campaign guidelines. Due to a possible delay in obtaining all the enrolment sequential organ failure assessment (SOFA) score variables necessary to fulfil the criteria for the latest 2016 sepsis definition, the 2012 Surviving Sepsis Campaign criteria and the quick SOFA tool will be used for inclusion. However, after study completion, when all admission SOFA scores will be available, all patients will be re-scored according to the Sepsis 3 definition.

Inclusion criteria for sepsis:

1. Documented or suspected infection

2. Systolic blood pressure = 100 mmHg, or receiving vasopressor (epinephrine, norepinephrine, dopamine)

PLUS one or more of the following:

A. Respiratory rate =22 breaths per minute or under oxygen therapy or mechanical ventilation B. Altered mental status (Glasgow Coma Scale = 14)

3. Fully informed written consent obtained, including written informed consent from a relative or parent/guardian in case of reduced consciousness and/or age < 16 years.

4. Age =12 years

5. Negative peripheral blood slide for any stages of malaria parasites and a negative rapid diagnostic test (RDT) for falciparum and vivax malaria.

6. Within 24 hours of hospital or ICU admission

Note: Positive blood or urine cultures not required as eligibility criteria due to limited microbiology laboratory availability.

II. Severe malaria criteria Using modified World Health Organization criteria for severe falciparum malaria, as defined previously.

• Any P. falciparum or P. vivax parasitaemia in adults, detected by asexual stages on a peripheral blood- slide or a positive RDT in combination with one or more:

i. GCS <11 ii. Hematocrit < 20% with parasite count >100,000/mm3 iii. Jaundice with parasite count >100,000/mm3 iv. Serum creatinine >3 mg/dL (or anuria) v. Hypoglycemia with venous glucose <40 mg/dL vi. Systolic blood pressure <80 mmHg with cool extremities vii. Peripheral asexual stage parasitemia >10 % viii. Peripheral venous lactate >4 mmol/L ix. Peripheral venous bicarbonate <15 mmol/L x. Respiratory distress/pulmonary edema: radiologically confirmed, or oxygen saturation <92% on room air with a respiratory rate >30/min, often with chest indrawing and crepitations on auscultation xi. Spontaneous bleeding xii. Generalized convulsions (=2 in 24 hours)

• Fully informed written consent obtained, including written informed consent from relative or parent/guardian in case of reduced consciousness and/or age < 16 years.

• Age =12 years

• Within 24 hours of antimalarial treatment

III. Uncomplicated malaria criteria (control group)

• P. falciparum slide positive (asexual stages) on peripheral blood slide or positive RDT in combination with none of the above severity criteria.

• Within 24 hours of start of antimalarial treatment

• Fully informed written consent obtained, including written informed consent from relative or parent/guardian in case of reduced consciousness and/or age < 16 years.

• Age =12 years

Exclusion Criteria

The participant may not enter the study if ANY of the following apply:

• Patients admitted with known malignancy or liver disease

• Recent surgery (as part of current admission)

• Trauma (resulting in current admission)

• Antimalarial treatment =24 hours prior to screening

Related Conditions & MeSH terms

• Malaria
• Sepsis
• Severe Sepsis
• Toxemia

Intervention

Procedure:
• Lung Ultrasound examination
Use of lung ultrasound to detect pulmonary complications
• Compression ultrasonography (CUS)
CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
• Echocardiography
Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
• Inferior Vena Cava ultrasound
Measurement of the inferior vena cava diameter
• Passive leg raising test (PLR)
Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
• Orthogonal polarization spectral imaging (OPS)
Measurement of capillary flow in the rectal microcirculation
• Urine collection (Foley catheter)
For urinalysis, biochemistry, urine microscopy, pH, and culture.
• Venous blood samplings
for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
• Electrocardiogram
all patients will have an ECG performed on enrolment as a non-invasive investigation
• GlycoCheck
GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.

Locations

Country	Name	City	State
Bangladesh	Chittagong Medical College Hospital	Chittagong

Sponsors (7)

Lead Sponsor	Collaborator
University of Oxford	Beth Israel Deaconess Medical Center, Chittagong Medical College and Hospital, Mahidol Oxford Tropical Medicine Research Unit, Malaria Research Group & Dev Care Foundation, Dhaka, Bangladesh, University of Amsterdam, University of British Columbia

Country where clinical trial is conducted

Bangladesh, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fluid balance volume at 24 hours	Fluid balance volume in milliliters calculated daily as inputs minus outputs.	On the first 24 hours from enrollment
Primary	Plasma lactate levels	Plasma venous lactate levels expressed in mmol/L	72 hours
Primary	Vasopressor therapy	Expressed as dichotomous variable, use of any vasopressor during the first 72 hours.	72 hours
Primary	Global ultrasound aeration score	The score ( range 0-36) is calculated over 12 lung zones where each zone is scored 0 to 3.	72 hours
Primary	Fluid balance volume at 48 hours	Fluid balance volume in milliliters calculated daily as inputs minus outputs.	On the first 48 hours from enrollment
Primary	Fluid balance volume at 72 hours	Fluid balance volume in milliliters calculated daily as inputs minus outputs.	On the first 72 hours from enrollment
Secondary	Plasma creatinine levels	Measured in millimoles per liter.	48 hours
Secondary	Positive chest X-ray for pulmonary edema (dichotomous variable)	Other measures evaluating pulmonary congestion	72 hours
Secondary	The ratio between pulse oxymetry hemoglobin saturation and the fraction of inspired oxygen (SpO2/FiO2 ratio).	Other measures evaluating pulmonary congestion	72 hours
Secondary	Proportion of fluid responsive patients	Fluid responsiveness is defined as a positive pulse pressure passive leg raise test (change in pulse pressure >10% after leg raise manouver) or cardiac output-guided passive leg raise test (change in cardiac output >10% after leg raise manouver). The passive leg raise test is performed both a standard maneuver (bed tilting) and a modified maneuver (manual leg raise).	72 hours
Secondary	Prolonged capillary refill time (dichotomous variable, defined as =3 seconds)	Other measures evaluating tissue perfusion	72 hours
Secondary	Skin mottling score (0-5)	Other measures evaluating tissue perfusion	72 hours
Secondary	Cardiac index (in liters per minute per square meter of body surface area)	Other measures evaluating tissue perfusion	72 hours
Secondary	Core-periphery temperature gradient(°C)	Other measures evaluating tissue perfusion	72 hours
Secondary	Proportion of patients at enrolment and during admission with a low cardiac index and hypoperfusion state.		72 hours
Secondary	Proportion of patients with microvasculature obstruction or abnormalities	Microvasculature obstruction and abnormalities are detected with orthogonal polarization spectral imaging (OPS); red cell deformability is studied by laser assisted rotational cell analyser (LORCA).	24 hours
Secondary	Proportion of patients that develop pulmonary edema and acute respiratory distress syndrome (ARDS).	Pulmonary edema is defined as the presence of 2 or more positive lung zones per hemithorax on the lung ultrasound. Acute respiratory distress syndrome is defined according to the Berlin Definition criteria.	72 hours
Secondary	Case fatality in first 30 days.		30 days
Secondary	Acute kidney injury (AKI)	Proportion of AKI as per Kidney Diseases Improving Global Outcomes definition: serum creatinine increase by = 3 mg/dl within 48 hours, or serum creatinine increase by = 1.5 times baseline, or urine volume <0.5 mg/kg/h for 6 hours. Outcome of AKI defined as renal recovery (time in days until creatinine returns to baseline).	At admission, up to day 14, and renal recovery by 30 days
Secondary	Proportion of patients that develop lower extremity deep venous thrombosis.	Deep venous thrombosis is defined as a positive compressive ultrasonography on femoral or popliteal veins of lower limbs.	72 hours
Secondary	Microbiological etiology of sepsis.	Results of blood culture and organism identified in case of positive result	72 hours
Secondary	Number of patients with ARDS according to the Kigali Modification of the Berlin Definition of ARDS		72 hours
Secondary	Diagnostic performance measures (sensitivity, specificity, positive predictive value, negative predictive value) of the digital microscope with expert microscopy as the gold standard		7 days